drugset
drugset / Trial / NCT05062200

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

NCT05062200 ↗

Phase 1 Completed 36 enrolled Janssen Pharmaceutical K.K.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of JNJ-77242113 after single ascending oral dose administration as an immediate-release (IR) tablet formulation in healthy Japanese participants and after single oral dose administration as an IR tablet formulation in healthy Chinese participants; and as a delayed release (DR) tablet formulation in healthy Japanese participants.

Timeline

Start
2021-10-25
Primary completion
2022-09-28
Completion
2022-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide — Oral

Indications

No indication recorded.